IP Library Granted Patent US 12,258,304
Granted Patent B2
US 12,258,304 · App. 17/612,647 · Granted Mar 25, 2025

Compounds and methods for treatment of bacterial infections

Inventors: Steven C. Almo (Pelham, NY); Tyler Grove (Bronx, NY); Lawrence D. Harris (Lower Hutt, NZ); Gary B. Evans (Lower Hutt, NZ)
Assignees: Albert Einstein College of Medicine; Victoria Link Limited
C07C229/38A61P31/04C07C63/14C07C323/62C07D213/79
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,304
App. No.
17/612,647
Granted
Mar 25, 2025
Kind
B2
Abstract

This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.

Claims (31)

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula I,

wherein:

R 1 in each instance independently is hydrogen or C 1-10 alkyl, wherein the C 1-10 alkyl is optionally substituted with one or more selected from the group consisting of a halogen, oxo (═O), OH, OC 1-4 alkyl, SC 1-4 alkyl, and arylC 1-6 alkyl;

R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, C 1-4 alkyl, CN, C 1-6 alkylCONH, C 1-6 alkylNHCO, C 1-6 alkylSO 2 NH, C 1-6 alkylNHSO 2 , and C 1-6 alkylSO 2 ;

X is O, S, NH or CH 2 ;

and

Z in each instance independently is C or N, provided that:

when a Z is N, the substituent R 2 , R 3 , R 4 , or R 5 attached thereto is void; and

when each Z is C, at least one of R 2 , R 3 , R 4 , and R 5 is chlorine or fluorine.

2. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is represented by Formula I-c,

wherein

R 1 is hydrogen or C 1-6 alkyl;

R 2 , R 3 , R 4 , and R 5 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, and C 1-6 alkyl.

3. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein R 1 is hydrogen.

4. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein at least one of R 2 , R 3 , R 4 , and R 5 is fluorine.

5. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein R 2 , R 3 , R 4 , and R 5 are each independently hydrogen or fluorine.

6. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of

7. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 .

8. The pharmaceutical composition of claim 7 , wherein the compound is selected from the group consisting of

9. A method of treating a bacterial infection or inhibiting the proliferation of bacteria in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof of claim 1 .

10. The method of claim 9 , wherein the compound or the pharmaceutically acceptable salt thereof is selective for the bacteria over Clostridium difficile, Escherichia coli or any other species that lacks the futalosine pathway.

11. The method of claim 9 , wherein the bacteria belongs to a genus selected from the group consisting of Helicobacter, Campylobacter, Streptococcus, Clostridium, Mycoplasma, Lactobacillus, Staphylococcus, Bifidobacterium, Rickettsia , and Brucella.

12. The method of claim 9 , wherein the bacteria belongs to Helicobacter genus.

13. The method of claim 9 , wherein the bacteria is Helicobacter pylori.

14. The method of claim 9 , wherein the subject is a human.

15. The method of claim 9 , wherein the compound is selected from the group consisting of

16. The method of claim 9 wherein the bacteria is Helicobacter pylori and the compound is

17. A method of inhibiting MqnE in a bacterial cell, comprising contacting the cell with an effective amount of the compound or the pharmaceutically acceptable salt thereof of claim 1 .

18. The method of claim 17 , wherein the bacterial cell belongs to a genus selected from the group consisting of Helicobacter, Campylobacter, Streptococcus, Clostridium, Mycoplasma, Lactobacillus, Staphylococcus, Bifidobacterium, Rickettsia , and Brucella.

19. The method of claim 17 , wherein the bacterial cell is Helicobacter pylori.

20. The compound or a pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 10, 2024
From: ALBERT EINSTEIN COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066255/0379 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2023
From: ALMO, STEVEN C.; GROVE, TYLER
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 064409/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2023
From: VICTORIA UNIVERSITY OF WELLINGTON
To: VICTORIA LINK LIMITED
Reel/Frame 064418/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2023
From: HARRIS, LAWRENCE DANIEL; EVANS, GARY B.
To: VICTORIA UNIVERSITY OF WELLINGTON
Reel/Frame 064418/0548 →
Continuity (2)
Provisional Application 62850245 · May 20, 2019
Related Publication 20220234995A1 · Jul 28, 2022
References Cited (7)
US 8114648B2 · Schultz et al. · 2012 [cited by applicant]
GB 2404855A · 2005 [cited by applicant]
Bulloch et al., ‘Identification of 4-Amino-4-deoxychorismate Synthase as the Molecular Target for the Antimicrobial Action of (6S)-6-Fluoroshikimate’, J. Am. Chem. Soc. 2004, vol. 126, pp. 9912-9913. p. 9912, Scheme 1. [cited by applicant]
Gonzalez-Bello, ‘Recently Developed Synthetic Compounds with Anti-infective Activity’, Current Opinion in Pharmacology, 2019, vol. 48, pp. 17-23 [Available online Apr. 18, 2019]. [cited by applicant]
Joshi et al., ‘Antibacterial Strategy Against H.Pylori: Inhibition of the Radical SAM Enzyme MqnE in Menaquinone Biosynthesis’, ACS Medicinal Chemistry letters, Feb. 15, 2019 (Feb. 15, 2019) vol. 10, pp. 363-366. [cited by applicant]
Mahanta et al., ‘Menaquinone Biosynthesis: Formation of Aminofutalosine Requires a Unique Radical SAM Enzyme’, J. Am. Chem. Soc. 2013, vol. 135, pp. 15318-15321. [cited by applicant]
International Search Report and Written Opinion mailed Aug. 14, 2020 for International Application No. PCT/US20/33756, 7 pages. [cited by applicant]